For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

In addition to improving heart failure symptoms, finerenone reduced the onset of new type 2 diabetes in patients with mildly ...

The trial results indicated minimal adverse events and no evidence of immune-mediated clearance following TX45 treatment.

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024SOUTH SAN ...

Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...

Finerenone has been shown to significantly reduce the risk for cardiovascular death in patients with heart failure in results from the FINEARTS-HF trial.

BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...

Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, ...

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...

The medication, finerenone, could be an effective therapy in people with heart failure who have mildly reduced or preserved ejection fraction, suggests the study, published Sunday in the New England ...